Effect of Sufentanil and Ropivacaine
Information source: Fudan University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Anesthesia Complications
Intervention: 0.25 sufentanil (Drug); 0.5µg/ml sufentanil (Drug); 0.1% ropivacaine (Drug)
Phase: N/A
Status: Completed
Sponsored by: Fudan University Official(s) and/or principal investigator(s): Zeyong Yang, M.D., Principal Investigator, Affiliation: Fudan University, Shanghai Jiaotong University
Summary
The investigators study the efficacy of epidural sufentanil/ropivacaine for analgesia labor
in primiparas so as to decrease perinatal complications of analgesia labor.
Clinical Details
Official title: Effect of 0.5µg/ml Sufentanil and Ropivacaine Towards Pregnant Women and Fetus in Analgesia Labor
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Primary outcome: VAS(visual analog pain score)
Detailed description:
A prospective study of 120 full-term parturients receiving labor analgesia were randomly
assigned into 2 groups: the 0. 5Sufen group (N=60), the 0. 25Sufen group (N=60).
Eligibility
Minimum age: 25 Years.
Maximum age: 35 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
1. Patients had regular prenatal examinations at the outpatient clinic;
2. They were between 25 to 35 years of age)
3. They had a gestational age ≥37 weeks and < 42 weeks;
4. They had an estimated fetal weight ≥ 2,500 g and < 4,200 g.
Exclusion Criteria:
- a history of spinal surgery,
- platelet count <100×109 /L ,
- coagulation disorder,
- sensorimotor disorder of lower extremity,
- leg pain,
- puncture point infection,
- heart disease history,
- pulmonary disease,
- liver and renal function disorder and
- a history of neuropsychiatry drugs.
Locations and Contacts
Additional Information
Starting date: April 2014
Last updated: June 30, 2015
|